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ABSTRACT
The Saccharomyces cerevisiae protein kinase Rad53
plays a key role in maintaining genomic integrity
after DNA damage and is an essential component of
the ‘intra-S-phase checkpoint’. In budding yeast,
alkylating chemicals, such as methyl methanesul-
fonate (MMS), or depletion of nucleotides by hydrox-
yurea (HU) stall DNA replication forks and thus
activate Rad53 during S-phase. This stabilizes stalled
DNA replication forks and prevents the activation of
later origins of DNA replication. Here, we report that a
reduction in the level of Rad53 kinase causes cells to
behave very differently in response to DNA alkylation
or to nucleotide depletion. While cells lacking Rad53
are unable to activate the checkpoint response to HU
or MMS, so that they rapidly lose viability, a reduction
in Rad53 enhances cell survival only after DNA
alkylation. This reduction in the level of Rad53 allows
S-phase cells to maintain the stability of DNA
replication forks upon MMS treatment, but does not
prevent the collapse of forks in HU. Our results may
have important implications for cancer therapies, as
they suggest that partial impairment of the S-phase
checkpoint Rad53/Chk2 kinase provides cells with a
growth advantage in the presence of drugs that
damage DNA.
INTRODUCTION
Eukaryotic cells have evolved efﬁcient surveillance mecha-
nisms that sense different kinds of DNA damage. These
mechanisms delay or arrest cell cycle progression and induce
repair processes that ensure genome integrity (1–3). It is
believed that the delay or arrest provides additional time
for cells to repair the damage efﬁciently prior to resuming
the cell division cycle. These surveillance mechanims are
signal transduction cascades called checkpoints that, when
activated, regulate repair responses including transcription
of the DNA damage response genes, activation of DNA repair
processes and recruitment of proteins to sites of DNA damage
to form, in some cases, foci at lesions (4–10). All major
components of checkpoint pathways are remarkably well
conserved in eukaryotes (5–8,10,11), in fact some of them
are implicated in embryonic development while others have
been found mutated in human cancer or in rare syndromes
that predispose to cancer (12–14). In the budding yeast
Saccharomyces cerevisiae the ATR-homologue Mec1 plays
a key role in the signalling cascade by phosphorylating down-
stream effector kinases in response to lesions in DNA and to
defects at DNA replication forks (15). In particular Mec1–
Ddc2 complexes are recruited to sites of damage or stalled
DNA replication forks (16–19) to, then, transduce the
checkpoint signal by phosphorylating effector kinases
Rad53 or Chk1 (15,20).
Recently it has been shown that the essential role of the
Mec1-Rad53 cascade is to maintain DNA replication forks
stability when cells face replication fork blocks or DNA
damage (21,22). In fact, both checkpoint proteins are
involved in a process of stabilization of DNA replication
forks that prevents them from collapsing spontaneously in
S-phase or after chemical exposure (21–26). mec1 and
rad53 mutant budding yeast cells are unable to recover
from any kind of stress that stalls progression of DNA
replication forks (22,27), indicating that the essential function
of the intra S-phase checkpoint is the recovery itself. The
intra S-phase checkpoint response also activates a Mec1/
Rad53-dependent mechanism that represses the ﬁring of
late and dormant replication origins (28–30). The absence
of this inhibitory mechanism explains the fast rate of DNA
synthesis in rad53 and mec1 mutant cells when DNA is
damaged (21,31).
In this study, which focuses on the characterization of
S.cerevisiae mutant cells with low levels of the Rad53 check-
point kinase, we ﬁnd that, as expected with a limited capacity
for checkpoint response, the reduction in Rad53 levels results
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in response to the depletion of nucleotides by hydroxyurea
(HU). However, we present clear evidence indicating that
this partial reduction of the Rad53 effector kinase strikingly
allows S-phase cells to maintain DNA replication fork stabil-
ity in response to methyl methanesulfonate (MMS)-mediated
DNA alkylation and that cells become resistant to the DNA
damaging agent.
MATERIALS AND METHODS
General methods of Molecular and Cellular Biology were
used as described by Sanchez et al. (32).
Strains, cell cycle control and checkpoint induction
The S.cerevisiae strains used in this work were 15Dau and
W303 backgrounds (as indicated). Yeast strains were grown
in rich YPA medium (1% yeast extract, 2% peptone) contain-
ing 2% glucose. For block-and-release experiments, cells
were grown in YPA with 2% glucose (except where indi-
cated) at 28 C and synchronised with a-factor pheromone
in G1 by adding 40 ng/ml (ﬁnal concentration, 2.5 h) for
the 15Dau strains or 7.5 mg/ml (2 h) + 2.5 mg/ml (one addi-
tional hour) for the W303 strains. Cells were then collected
by centrifugation and released in the presence of MMS or
HU as indicated. Overexpression experiments with cells
grown in YPA medium with 2% rafﬁnose at 28 C were
conducted by adding 0.3% galactose (to induce) or 2% glu-
cose (to repress) to the medium and further incubating
with/without MMS or HU as indicated. Proteolysis in degron
strains was induced from asynchronous cultures of cells
grown at 24 C in YP medium containing 2% Rafﬁnose as
the carbon source and 0.1 mM CuSO4. To inactivate Rad53
degron fusion protein, expression of UBR1 was induced by
addition of 2.5% Galactose (ﬁnal concentration) to the med-
ium (still containing 0.1 mM CuSO4) for 30 min at 24 C
before changing to YPGal medium prewarmed at 37 C, and
continuing incubation for 120 min. Experiments in Petri
dishes with degron strains were performed at 24 or 37 Ci n
YPD (containing 0.1 mM CuSO4), YPRaf (containing
0.1 mM CuSO4), or YPGal as required. FACS analysis of
DNA content was performed as described (32).
Rad53-Ha, Rad53 degron fusion strains and RAD53
deletion strains
To construct the rad53Ha allele (in all genetic backgrounds)
the single step PCR-based gene modiﬁcation strategy by
Longtine et al. (33) was used. The oligonucleotides used
were 50-AAGGTTAAAAGGGCAAAATTGGACCAAACC-
TCAAAAGGCCCCGAGAATTTCAATTTTCGCGGATCC-
CCGGGTTATTAA-30 and 50-GGTATCTACCATCTTCTC-
TCTTAAAAAGGGGCAGCATTTTCTATGGGTATTTGT-
CCTTGGGAATTCGAGCTCGTTAAAC-30. The selection
marker used was KANMX6, which allows selection with
Geneticin, or TRP1. The resulting genomic constructions
were conﬁrmed by PCR and sequencing. A similar strategy
was employed to construct GAL1,10: rad53Ha by gene tar-
geting of rad53Ha strains. The oligonucleotides used in this
case were 50-AAAGGACGGTAGAGATTATTGGAAGAC-
AAACTAATTTTGTATATGCATTCGATTTGAATTCGA-
GCTCGTTTAAAC-30 and 50-AAAACCTTTGAGTAGCCT-
GCGTGGATTGCTGTGTGGGTTGTGTAATATTTTCCA-
TCATTTTGAGATCCGGGTTTT-30. SML1 deletions were
generated similarly. The oligonucleotides used were 50-GAT-
CTTACGGTCTCACTAACCTCTCTTCAACTGCTCAAT-
AATTTCCCGCTCGGATCCCCGGGTTAATTAA-30 and 50-
CAGAACTAGTGGGAAATGGAAAGAGAAAAGAAAA-
GAGTATGAAAGGAACTGAATTCGAGCTCGTTTAAAC-
30 for the 15Dau strain, and for the W303 strain the oligonu-
cleotides used were 50-ATCTGCTCCTTTGTGATCTTACG-
GTCTCACTAACCTCTCTTCAACTGCTCCGGCATCAG-
AGCAGATTGTAC-30 and 50-AAGGAACTTTAGAAGTC-
CATTTCCTCGACCTTACCCTGGTTGAACATAGAGTA-
TTTCACACCGCATATGATC-30.I nsml1 deletions the
selectable marker used was HIS3.
To construct the rad53-tpd heat-inducible degron strain the
same single step-PCR-based gene modiﬁcation was used
(33), in a yeast strain in which the only copy of the UBR1
gene was regulated by the galactose-inducible GAL1, 10 pro-
moter (34). The oligonucleotides used were 50-AGGACGGT-
AGAGATTATTGGAAGACAAACTAATTTTGTATATGC-
ATTCGAATTAAGGCGCGCCAGATCTG-30 and 50-CTTT-
GAGTAGCCTGCGTGGATTGCTGTGTGGGTTGTGTAA-
TATTTTCCATGGCACCCGCTCCAGCGCCTG-30. Again,
the selection marker used was KANMX6, which allows selec-
tion with Geneticin.
In all cases correct integrations were conﬁrmed by PCRs
using combinations of oligonucleotides corresponding to
sequences either side of the integration site or within the
inserted cassette.
Western blot and in situ autophosphorylation assays
Cells extracts were prepared by standard yeast protein proto-
cols (35). Immunoblotting was carried out with anti-Rad53
(gift of Dr J. F. X. Difﬂey) or with anti-Rad53 (#sc-6749)
from Santa Cruz Biotechnology, Inc., used as indicated by
the supplier. In situ autophosphorylation assays (ISA) were
carried out as described (35,36).
Two-dimensional DNA gels (2D-gel analysis)
DNA samples for neutral-neutral two-dimensional gel
electrophoresis were prepared and analyzed as described
previously (22,37,38). DNA was cut with the NcoI restriction
enzyme and hybridized to probes spanning the ARS306 and
ARS501 origins of DNA replication.
RESULTS
Carboxy Ha-tagging of Rad53 enhances cell survival
following DNA alkylation
MMS modiﬁes both guanines and adenines to methyl
derivatives causing DNA base mispairing, hence inducing
DNA damage and slowing down progression through DNA
replication (21,25,31,39). RAD53 has a central role in the
checkpoint response to this alkylating chemical. Exposure
to MMS leads to Rad53 phosphorylation and checkpoint
activation (25,31,40,41). Here we characterised a RAD53
allele tagged with three Ha epitopes (rad53Ha) and found
major differences in the cellular responses to different
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comparable to the wild-type control and tagged cells
progressed through a normal S-phase without losing viability
(Figure 1), suggesting that the rad53Ha allele was fully func-
tional. However, we found that cells carrying the Ha-tagged
allele were hyposensitive to low concentrations of MMS.
This resistance to the effect of the DNA-alkylating agent
was independent of the strain background used for the
analysis (Figure 1A). In contrast, a 10-fold dilution assay in
plates with 50 mM HU, a ribonuclease reductase inhibitor
(42), showed that rad53Ha cells were hypersensitive to the
drug (Figure 1A). The level of response was better than in
a strain deleted for RAD53, indicating that rad53Ha mutant
cells were partially active in the checkpoint response to
blocks in DNA replication. Interestingly, we have also
found that rad53Ha cells were partially resistant to cisplatin.
However, they were not sensitive to ultraviolet, camptothecin
(CPT) or bleomycin treatments (Supplementary Data). We
conclude that rad53Ha is a mutant allele of RAD53.
When S.cerevisiae cells are treated with drugs that
interfere with S-phase progression, such as MMS or HU,
the Mec1 and Rad53 checkpoint kinases are sequentially acti-
vated to respond to the DNA stress (15,43). We then analysed
checkpoint activation and found that rad53Ha cells had
low levels of the Rad53 kinase. The phosphorylation of
Rad53 changes its electrophoretical mobility in denaturing
PAGE-gels and has been related to its activation (35).
When cells were exposed to HU, MMS or bleomycin, Rad53
and Rad53Ha proteins became phosphorylated as judged by
the shift in their mobility; indicating that the wild-type and
the mutant-form proteins were active (Figure 1B). In block
and release experiments with a-factor-synchronised cells,
we found no differences between Ha-tagged or Rad53 wild-
type controls in the temporal pattern of activation of the
checkpoint kinase. However, rad35Ha cells accumulated
lower levels of the kinase than wild-type cells.
We next compared the activity of the Rad53 kinase in
wild-type and rad53Ha strains. In keeping with the differ-
ences observed in the level of the checkpoint protein, an
ISA (35) revealed that rad53Ha cells contained an active
Rad53Ha protein kinase that was able to phosphorylate itself
and that accumulated low amounts of the checkpoint kinase
compared to the wild-type (Figure 1B).
DNA damage and replication stress induced
transcription in rad53Ha mutant cells
In S.cerevisiae activation of the checkpoint kinase cascade
(Mec1/Rad53/Dun1) in response to DNA replication stress
or DNA damage during S-phase rapidly induces the transcrip-
tion of RNR genes, including RNR1, RNR2, RNR3 and RNR4
(44–47). To understand the consequences of reducing the
cellular level of Rad53 checkpoint kinase in the transcrip-
tional induction response we next analysed the expression
of the RNR2 gene after MMS or HU treatments. The RNR2
gene codes for one of the two essential small subunits of
the ribonucleotide reductase complex in S.cerevisiae. RNR2
mRNA level is highly induced in response to the stress of
DNA damage or nucleotide depletion (45,48). Northern
analysis showed that RNR2 gene expression was similarly
downregulated upon induction of checkpoint response to
both MMS and HU treatments in rad53Ha mutant cells
compared to wild-type controls (Figure 2). Comparable
results were obtained when HUG1 expression was analysed
(data not shown). HUG1 is another component of the
checkpoint response in budding yeast (49). These data indi-
cate that a reduction in Rad53 levels limits the transcriptional
response of the checkpoint cascade to replication blocks and
DNA alkylation.
Defects of rad53Ha are not bypassed by deletion
of SML1
In the budding yeast S.cerevisiae, MEC1 and RAD53 are
essential for cell growth and checkpoint response. The cell
growth defect is the consequence of the Mec1 and Rad53-
protein kinases control of dNTP production. Consistently,
cell viability is restored in cells lacking MEC1 or RAD53
by deletion of SML1, a physiological inhibitor of the ribonu-
cleotide reductase complex (42,50–52). We have shown
above that rad53Ha cells are resistant to MMS and sensitive
to HU (Figure 1). One possibility is that the observed effects
of HU and MMS in rad53Ha cells could simply be explained
by the effect of the low levels of expression of RNR2 gene in
Ha-tagged cells when exposed to the drugs (Figure 2). In such
case, deletion of SML1 would rescue rad53Ha-associated HU
sensitivity and MMS resistance. To test this possibility we
deleted SML1 in rad53Ha cells and tested double mutants
Figure 1. The Ha carboxy-terminal tagging of Rad53 reduces protein levels
and renders cells sensitive to HU and resistant to MMS. (A) 10-fold serial
dilutions of cultures of wild-type and rad53Ha mutant cells growing in
YPAD and spotted onto YPAD plates with or without HU (50 mM) or MMS
(0.01%) as indicated. Note that the assay was performed in the 15Dau and
W303 S.cerevisiae strain backgrounds. (B) Immunoblot analysis and In situ
Kinase Assay of Rad53 in asynchronous cultures of wild-type and rad53Ha
strains (A), or in cells treated for 90 min with 200 mM HU (H), or with
0.033% MMS (M), or with 10 mU/ml of Bleomycin (B) (Note: a longer
exposure of the western and ISA were needed to detect Rad53Ha in
bleomycin samples). (C) Cultures of wild-type and rad53Ha strains growing
exponentially in YPAD medium were synchronised in G1 with alpha-factor
pheromone at 28 C and then released into fresh YPAD medium at the same
temperature to allow cells to initiate S-phase synchronously. Samples were
taken at indicated intervals and processed for viability assays and percentage
of viables was plotted.
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we found that deletion of the ribonucleotide reductase SML1-
encoding gene had minor effects on rad53Ha-associated
phenotypes, Dsml1 rad53Ha cells were resistant to MMS
and hypersensitive to HU as found for rad53Ha cells.
An increase in Rad53Ha protein levels restores the
wild-type response to MMS
If low levels of the Rad53 checkpoint protein lead to all
defects observed in rad53Ha S.cerevisiae cells, it could be
predicted that higher levels of Rad53Ha protein should rescue
the defective responses to MMS and HU. We therefore con-
structed a GAL1,10:rad53Ha strain (in a Dsml1 background
to ensure cell viability) that only expressed high levels of
Rad53Ha when induced. As expected of a strain conditionally
deleted for RAD53, GAL1,10:rad53Ha, cells were hypersen-
sitive to HU and MMS (Figure 4A, GAL1 OFF plates), com-
parable to a rad53 deletion mutant strain (15,43,53,54). We
then tested the levels and the kinase activity of Rad53Ha pro-
tein with the GAL1,10:rad53Ha strain (Figure 4B). We found
that indeed they were fairly similar to those in wild-type cells
(Figure 4B, lower panels). Accordingly, the resistance to
MMS associated with rad53Ha cells was rescued by
Rad53Ha overexpression and likewise the hypersensitivity
of these cells to HU was suppressed (Figure 4A), indicating
that the defects observed in Rad53Ha-tagged strains were
directly related to insufﬁcient protein levels.
rad53-tpd: a degron allele of RAD53 with low levels
of the checkpoint kinase
To further support our hypothesis that resistance to MMS-
mediated DNA damage and sensitivity to HU-induced
replication blocks was a simple consequence of reducing
Rad53 levels we looked for alternative situations in which
we could limit the amount of the Rad53-checkpoint kinase.
We reasoned that depletion of the mRNA by transcriptional
repression (tet02 or GAL1 systems) would not be an efﬁcient
mechanism to limit Rad53 levels because the checkpoint
protein is fairly stable (S. Ufano and A. Bueno, unpublished
data). A method called ‘heat-inducible-degron’ has been
described that allows any essential protein to be depleted
rapidly and conditionally by targeting the protein for degrada-
tion at 37 C (34,55). We fused a ‘heat-inducible-degron’ to
the amino terminus of Rad53 and, in addition, we screened
for (Rad53-) degron strains that were viable at 37 C and
selected those where cell size was markedly heterogeneous
(suggesting insufﬁcient inactivation of the protein). We
Figure 2. Limited RNR2 expression in rad53Ha mutant cells in response to
blocks in DNA replication and DNA damage. Northern blot analyses of RNA
isolated from wild-type and rad53Ha cells treated with HU (200 mM) (A)o r
MMS (0.033%) (B). Wild-type and Rad53Ha-tagged cells were synchronised
with a-factor and then released in the presence of HU or MMS. RNA samples
were isolated at the times indicated and then electrophoresed, blotted to nylon
membranes and the membranes were probed for RNR2 expression. The
loading control is the 18S rRNA stained with methylene blue.
Figure 3. Sensitivity assay to HU and MMS-mediated DNA damage in wild-
type, rad53Ha, Dsml1 and rad53Ha Dsml1 mutants. 10-fold serial dilution
assays of cultures of the indicated strains exposed to sublethal concentrations
of DNA replication inhibitor HU or DNA alkylating chemical MMS.
Figure 4. Suppression of MMS-induced DNA damage and HU-replicative
stress sensitivity defects by increased expression of the rad53Ha allele.
(A) 10-fold serial dilution assay of indicated strains. Cells growing in YPAD
medium were spotted onto YPAD (2% glucose, labeled as GAL1 OFF)o r
YPARG (0.3% galactose, 1% raffinose, labeled as GAL1 ON). Petri dishes
with no drug (control), with 10 mM HU or with 0.015% MMS (as indicated),
were incubated for 48 h at 28 C and then photographed. (B) Analysis of
Rad53 protein levels (Immunoblot) and Rad53 activity (ISA) in asynchronous
(control) HU- and MMS-treated cultures of wild-type (1), rad53Ha (2) and
GAL1,10:rad53Ha sml1D (3) strains. When treated, yeast cultures were
exposed to HU or MMS (as indicated) for 90 min.
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selected strains to express levels of Rad53 sufﬁcient to
support cell viability but insufﬁcient to respond properly to
genotoxic insults. One of the strains was choosed for further
work (Figure 5), we named it rad53-tpd (where tpd denotes a
temperature-sensitive partial degron, to follow previous
nomenclature). As expected rad53-tpd induced a partial
degradation of Rad53 at 37 C (Figure 5A). At this tempera-
ture the level of Rad53-tpd protein was higher than in
rad53Ha cells but lower than in wild-type cells. Importantly,
when assayed in the presence of drugs we noticed that cells
were clearly sensitive to HU (not to the same extent as
Drad53 Dsml1 cells) and almost as resistant as wild-type
cells to MMS (Figure 5B). We also noticed that rad53Ha
cells were more resistant to the action of the alkylating
agent than rad53-tpd. rad53Ha and rad53-tpd behave
dissimilarly in HU and MMS most likely because of differ-
ences in levels of the Rad53Ha and Rad53-tpd proteins
(Figure 5A). However, these results support our observation
that reducing the level of the Rad53-effector kinase causes
cells to behave very differently in response to MMS-mediated
DNA alkylation or to HU-induced nucleotide depletion.
DNA replication fork stability upon MMS- or
HU-induced stalling in rad53Ha mutant cells
In response to MMS wild-type S.cerevisiae cells slowed
down progression through S-phase. In contrast, rad53
deletants passed through S-phase as fast as untreated cells,
losing their viability (21,29). These phenotypes are inter-
preted as the consequences of inappropriate activation of
late and dormant origins of DNA replication and the collapse
of DNA replication forks (21,29). Accordingly, we analysed
S-phase progression in MMS-treated rad53Ha mutant cells
(Figure 6) and found that a-factor-presynchronised
Rad53Ha-tagged cells rapidly doubled their DNA content,
as measured by FACS analysis (Figure 6B). This was in
contrast to wild-type controls, which slowed progression
through DNA replication, as previously reported (29,31).
Consistently, the late origin ARS501 was not inhibited in
rad53Ha mutant cells (Figure 6A; see arrow in 30 min
rad53Ha sample). However, 2D-gel analysis showed no
indication of DNA replication fork collapse in replicating
ARS306 or ARS501 genomic sequences, while western blot
and ISA conﬁrmed low levels of the checkpoint kinase in
mutant cells (Figure 6C). This is in sharp contrast to collaps-
ing structures observed in replicating ARS306 in cells deleted
for RAD53 when treated with MMS (Figure 6D and F), as
previously described by Lopes et al. (26).
We then analysed the replication intermediates in rad53Ha
cells released from a G1 block in the presence of HU and
found that, in agreement with their hypersensitivity to the
drug (Figure 1), the DNA replication forks collapsed
(Figure 7). These unusual replication intermediates were
similar to abnormal DNA structures previously observed in
HU-treated rad53-kinase dead mutants (22).
Our results show that rad53Ha cells have enough
checkpoint effector kinase molecules to deal with fork stabil-
ity but not enough to prevent DNA replication late origins
from ﬁring in the presence of the DNA-alkylating agent,
contrasting with their own defects regarding fork collapse
in HU.
Premature checkpoint inactivation in cells with low
levels of Rad53 kinase
We next became interested in the analysis of rad53Ha
resistance to MMS. Recovery from a DNA damaging insult
requires down-regulation of the Rad53 checkpoint kinase
(35). Rad53 down-regulation allows cells to reset cell cycle
progression (41). Although rad53Ha cells harboured low
levels of the checkpoint kinase, they inactivated it when
recovering from MMS or HU treatments as in wild-type
cells, as judged by their pattern of dephosphorylation
(Figure 8). This indicates that Rad53Ha checkpoint kinase
is properly dephosphorylated as cells recover from drug-
induced DNA replication blocks or DNA damage. However,
consistent with DNA replication fork collapse in HU
(Figure 7), we noticed that Ha-tagged cells maintained
Rad53Ha-associated kinase activity longer than wild-type
controls (Figure 8A). This indicates that cells dealing with
fork collapse sense the damage and maintain an active
checkpoint.
To understand the DNA damage resistance of rad53Ha
mutant cells observed on MMS plates, we also compared
the activation of Rad53 checkpoint kinase in wild-type
and rad53Ha cells when exposed to MMS for long periods
of time. Therefore, we analysed the relative concentration
and activity of Rad53 in cells exposed to different doses
of the DNA alkylating drug (Figure 9). Rad53 remained
active throughout all MMS treatments in wild-type controls.
However, Rad53Ha in tagged cells rapidly became
down-regulated after an initial activation upon drug exposure,
even at the higher doses used, implying that rad53Ha
cells had prematurely down-regulated Rad53-associated
kinase activity in continuous exposure to the alkylating
DNA-damaging agent.
Because this premature down-regulation of Rad53Ha
kinase could enhance the mutation rate and genomic
Figure 5. The partial inactivation of Rad53 by fusion to a heat-inducible
degron renders cells hypersensitive to HU and wild-type-like to MMS. (A),
left panels, Western blot analysis of a Rad53-tpd protein in mutant strains
asynchronously growing (A) or after partial inactivation of the degron fusion
protein at indicated intervals. (A), right panels, comparison of protein levels
of Rad53-tpd with appropriate controls (Rad53Ha and wt Rad53). The protein
loading controls are portions of respective gels stained with Ponceau.
(B) Serial dilutions were made of a Rad53 degron strain (rad53-tpd) together
with rad35Ha, Drad53 Dsml1 and wild-type controls.
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to canavanine resistance (56) on rad53Ha-tagged mutant
cells exposed to MMS and found that it was almost 2-fold
higher than in wild-type cells (Figure 10), suggesting that a
reduction in cellular levels of the kinase decreases replication
ﬁdelity in the presence of the alkylating agent and
consequently increases genetic instability.
Since Rad53Ha is prematurely dephosphorylated in the
continuous presence of MMS and this down-regulation
results in a short cell cycle arrest, we were interested in
understanding whether the PI3-kinases Mec1 and Tel1 were
continuously required for rad53Ha resistance to the
DNA alkylating drug. For this purpose, we studied the effect
of caffeine (1,3,7-trimethylxanthine) in rad53Ha resistance
to MMS. In budding yeast caffeine has mutagenic effects
that appear to be mediated through the inhibition of PI3-
related kinases Tel1 and Mec1 (57). Viability was checked
in rad53Ha cells and wild-type controls ﬁrst treated
with MMS and then with or without caffeine (in the presence
of MMS). We found that rad53Ha cells treated with
caffeine were less viable than controls lacking the drug
(Figure 11). This result clearly suggests that rad53Ha resis-
tance to MMS-mediated DNA damage depends on functional
Mec1 and/or Tel1 kinases. Importantly, this evidence, in the
context of the premature dephosphorylation of Rad53Ha,
also supports the view that a minimal concentration of
Rad53 protein may be required for the maintenance of the
hyperphosphorylated state of the checkpoint kinase, more
likely by the autophosphorylation activity of Rad53 kinase.
DISCUSSION
We have explored the consequences of reducing Rad53
protein levels in S.cerevisiae cells when dealing with blocks
to DNA replication or DNA damage induced by an alkylating
chemical. The results of our studies indicate that the limita-
tion of Rad53 protein leads to HU sensitivity and checkpoint
impairment in response to depletion of nucleotides, however,
unexpectedly, it also leads to a dramatic increase in cellular
resistance to MMS-induced DNA damage.
By tagging the carboxy-terminus of the Rad53 protein with
the Haemmaglutinin epitope we have generated a yeast strain
with a low level of the checkpoint protein. How does the
C-terminal tagging of Rad53 cause cells to accumulate low
amounts of the checkpoint protein? We have studied the
stability of Rad53Ha and found that the tagged protein
is unstable (S. Ufano and A. Bueno, unpublished data).
However, yeast cells carrying the rad53Ha allele are viable
and show no obvious defects in the growth and cell cycle
parameters analysed. In fact, rad53Ha cells are viable even
without the deletion of SML1 gene (encoding a ribonucleotide
reductase inhibitor), as is required not only for rad53 but also
for mec1 null mutants (42,50,51). Thus, the checkpoint kinase
level in rad53Ha cells appears to be sufﬁcient to induce the
degradation of Sml1 protein every S-phase. Consistently, S-
phase progression is normal as observed by FACS analysis
of DNA content (data not shown). The Ha-tagged Rad53
checkpoint kinase is properly and promptly activated in
response to HU and MMS, as shown by western and ISA.
However, rad53Ha strains are sensitive to HU but resistant
to MMS. These defects in rad53Ha cells are directly
attributable to the reduction in the level of the checkpoint
kinase, because a GAL1,10-regulated increase of the
Ha-tagged protein restores wild-type like responses to HU
and MMS. These experiments demonstrate that the
Rad53Ha protein kinase is fully functional because the check-
point response is restored when normal levels of the
checkpoint protein are reached. Further support for our
hypothesis comes from the analysis of the rad53-tpd degron
strain that we have generated. Despite the fact that rad53-tpd
cells are not resistant to MMS (at least to the same extent
as rad53Ha cells) they are as resistant as wild-type cells to
the alkylating agent, contrasting to their hypersensitivity to
HU. Thus, our study identiﬁes two different mutants with
low Rad53 levels, rad53Ha and rad53-tpd, that behave
similarly in dealing with HU-induced DNA replication blocks
or DNA alkylation damage.
When treated with the alkylating agent MMS, rad53Ha
cells progress through S-phase as fast as fully defective
mutants (21,29). Accordingly, the ARS501 late DNA replica-
tion origin is activated and rad53Ha cells had a low level of
the checkpoint kinase. Our data again suggest a defect asso-
ciated with an insufﬁcient number of molecules of the check-
point protein to prevent the activation of late origins, as in
rad53D sml1D mutants (21,28,29). However, rad53Ha strains
are resistant to MMS and, remarkably, DNA replication forks
remain stable in the presence of the DNA alkylating agent,
contrasting with fork instability in rad53 null mutants
(21,25,26). Our data indicate that rad53Ha cells have enough
checkpoint effector kinase molecules to deal with fork stabili-
sation but not enough to prevent late DNA replication origins
from ﬁring in the presence of the alkylating agent. These
ﬁndings are consistent with earlier evidence from the analysis
of mec1-100 mutants, suggesting that the essential function
of the checkpoint response to DNA damage is to maintain
DNA replication fork stability (25), and, importantly, indicate
a hierarchy of Rad53 functions in checkpoint response
to MMS.
Figure 6. MMS-induced S-phase DNA damage checkpoint in rad53Ha mutant cells. Cultures of wild-type and rad53Ha mutant cells presynchronised in G1 with
a-factor were released into fresh YPAD medium containing 0.033% MMS to induce the intra S-phase DNA damage checkpoint response. Samples were taken at
the indicated intervals and processed for FACS analysis, 2D-gel analysis of ARS306 and ARS501, Western blotting and ISA assays of Rad53. (A) Genomic DNA
samples were prepared from aliquots at the indicated intervals and cut with NcoI, restriction fragments were electrophoresed in 2D-gels, transferred to nylon
membranes and hybridized to probes spanning the ARS306 and ARS501 origins of DNA replication. (B) FACS analysis of the DNA content of rad53Ha and wild-
type control cells in response to MMS treatment. Note that rad53Ha mutants passed through S-phase faster than wt controls (samples indicated by arrows).
(C) Protein extracts from aliquots from the same samples were analysed by Western blot assays with anti-Rad53 antibody or In Situ Authophosphorylation assays
(ISA), as indicated, to test the activation of Rad53. A cross-referenced sample (labelled C) was used in both the Western and ISA assays that corresponded to the
120 min sample of rad53Ha or wild-type experiments respectively. (D) Genomic DNA samples from Drad53 Dsml1 cells treated with MMS were prepared at
indicated intervals as in section A and hybridized to the ARS306 probe. Note that replication in these Drad53 Dsml1 cells starts 15 min later than in wild-type and
rad53Ha cells in A, and also that small Ys and cone-shaped signals are evident from 45 min (to the end of the experiment) indicating genuine DNA replication
fork collapse. (E) FACS analysis of Drad53 Dsml1 cells in D treated with MMS. (F) Comparison of replication intermediates in rad53HA and Drad53 Dsml1 cells
(cone-shaped signals and small Ys are indicated by arrows in the Drad53 Dsml1 mutant).
5858 Nucleic Acids Research, 2006, Vol. 34, No. 20Interestingly rad53Ha strains are sensitive to HU and show
every phenotype previously described for rad53 fully
defective or kinase dead mutants in the response to this
ribonucleotide reductase inhibitor drug (22,28–30), indicating
that a low number of molecules of active Rad53 per cell is not
enough to properly respond to a block in DNA replication
caused by HU. Accordingly, we have observed a signiﬁcant
degree of DNA replication fork collapse. Thus, our study
identiﬁes important differences in stalled DNA replication
fork stability in MMS and HU and strongly suggests that
replication fork stabilization in HU or MMS are genetically
separable functions. Future studies will test this hypothesis.
The inactivation of Rad53Ha when cells are recovering cell
cycle progression after a MMS block and release mimics the
pattern of the Rad53 wild-type protein that it is indeed
comparable to previous reports on the Rad53 checkpoint
effector kinase (22,35). We have observed that a lower
level of the checkpoint kinase in rad53Ha cells implies a
earlier exit from the block (upon release from drug treat-
ment). Accordingly, the rad53Ha mutation increases genetic
instability. In experiments of continuous exposure to the
DNA damaging agent, we have shown that the premature
inactivation of Rad53Ha precedes cell cycle resetting and
so correlates with the resistance to the DNA alkylating
agent. However, wild-type levels of Rad53 maintain check-
point activation in response to MMS exposure [(21,25) and
this work]. Thus, a reduction in the number of Rad53 mole-
cules per cell results in premature checkpoint down-
regulation, allowing cells to reset the cell cycle and prolifer-
ate. Our ﬁndings suggest that the premature inactivation of
Figure 7. Effect of HU treatment on initiation from an early (ARS306) origin
of DNA replication in rad53Ha cells. (A) wild-type and rad53Ha mutant
cells were grown in YPAD medium to exponential phase, synchronised with
a-factor in G1 and then released into fresh YPAD medium containing 0.2 M
HU. Genomic DNA was prepared from cells at indicated intervals (from the
release) and cut with NcoI. Restriction fragments were electrophoresed in
N:N 2D-gels, transferred to nylon membranes and hybridized to a probe
spanning the ARS306 early origin of replication. (B) rad53Ha mutant cells
acumulate abnormal DNA replication structures (cone-shaped signals and
small Ys as indicated by arrows). A drawing of the abnormal intermediates
related to DNA replication fork collapse, according to Lopes et al. (2001), is
also shown.
Figure 8. Recovery from replication arrest (HU) and DNA damage (MMS) in
rad53Ha cells. Wild-type and rad53Ha mutant cells growing exponentially at
28 C were first synchronised in G1 with a-factor and then released into
S-phase in fresh YPAD medium in the presence of HU (A) or MMS (B) and
incubated for a further 90 min. Cultures were then released from drug
exposure into fresh YPAD medium and further incubated at 28 C (recovery).
Protein extracts were prepared at the indicated intervals and analysed by
western blotting using an anti-Rad53 polyclonal antibody and in situ kinase
assay (ISA).
Nucleic Acids Research, 2006, Vol. 34, No. 20 5859Rad53Ha kinase leads to resistance to the DNA alkylating
agent. We have also found that rad53Ha cells are partially
resistant to cisplatin (cis-diamminedichloroplatinum: a plat-
inum compound widely used in cancer chemotherapy). It is
of interest to study whether or not the resistance to cisplatin
is, as expected, the consequence of a similar checkpoint
defect. The mechanism of rad53Ha resistance to cisplatin
will be the subject of future studies.
It is important to emphasise that rad53Ha defects are not
equivalent to the defects described for orc2-1 in S.cerevisiae.
orc2-1 thermosensitive mutant cells compromise the activa-
tion of Rad53 in S-phase by means of replication stress or
DNA damage, resulting in cells that are sensitive to both
HU and MMS (58). In contrast, rad53Ha cells have a genuine
defect in kinase levels but the kinase is promptly activated in
response to replication blocks (HU) or DNA damage (MMS)
(Figures 1B and 6C), resulting in cells sensitive to HU but
resistant to MMS-induced DNA damage. It is also of interest
to compare rad53Ha with mec1-100 strains. mec1-100
mutants are deﬁcient in the timing of checkpoint activation,
resulting in cells sensitive to blocks in DNA replication but
wild-type-like to MMS-induced DNA damage (40). Consis-
tently, Rad53 checkpoint kinase levels reach wild-type levels
in mec1-100 cells (40).
Finally, our ﬁndings in yeast may have important
implications for cancer-therapy and they suggest an explana-
tion for the role of mutations that reduce checkpoint activity
in human lung cancer (59,60). These mutations were shown
to confer resistance to radiation-induced DNA damage.
In particular, it has been shown that a mutation in CHK2
related with human lung cancer (59,61) encodes an unstable
protein that is expressed only at a signiﬁcantly reduced level
of the wild-type (20% of the wt level) (59). The authors
suggested that reduced expression of Chk2 may be an impor-
tant inactivating mechanism of the DNA damage checkpoint
pathway, contributing to the development of this fatal adult
lung cancer. Our work suggests that such change may down-
regulate the checkpoint response and thus favour tumour cell
Figure 9. A reduction in the levels of the Rad53 checkpoint kinase causes
cells to inactivate the checkpoint kinase in response to continuous MMS-
induced DNA damage. (A–C) Cultures of wild-type and rad53Ha cells
synchronised in G1 with a-factor were released into S-phase in fresh YPAD
medium in the presence of the indicated MMS concentrations. Samples were
taken at the indicated intervals and prepared for immunoblot and in situ
kinase assays (ISA).
Figure 10. Forward mutation analysis in wild-type and rad53Ha strains.
Canavanine resistance was assayed in rad53Ha and wild-type control cells
treated with 0.015% MMS at 28 C for 0, 8 and 24 h. A plot of the resulting
forward mutation rate is shown.
5860 Nucleic Acids Research, 2006, Vol. 34, No. 20proliferation upon DNA damaging therapy. Accordingly, pre-
vious work on p53 mutants indicated that checkpoint defects
make cells resistant to irradiation or treatment with chemo-
therapeutic compounds (62) and established an experimental
correlation between p53 mutations and poor prognosis in
cancer development (63,64). Our work suggests that in the
case of cells that are partially defective in Rad53/Chk2
checkpoint pathways, it may be more effective to use drugs
that strongly stall the progression of DNA replication forks.
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